These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23029104)

  • 1. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
    Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
    PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CDC73 gene mutation and parafibromin expression status of parathyroid carcinoma in Chinese].
    Kong J; Wang O; Nie M; Shi J; Jiang Y; Li M; Xia WB; Meng XW; Xing XP
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(42):3364-8. PubMed ID: 24418033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
    Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
    Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
    Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
    Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
    Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
    PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
    Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
    Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
    Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
    Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data.
    Zhu R; Wang Z; Hu Y
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):295-302. PubMed ID: 31945198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses.
    Cavaco BM; Santos R; Félix A; Carvalho D; Lopes JM; Domingues R; Sirgado M; Rei N; Fonseca F; Santos JR; Sobrinho L; Leite V
    Endocr Pathol; 2011 Mar; 22(1):44-52. PubMed ID: 21360064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the genetic basis of parathyroid carcinoma.
    Gill AJ
    Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas.
    Haven CJ; van Puijenbroek M; Tan MH; Teh BT; Fleuren GJ; van Wezel T; Morreau H
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):370-6. PubMed ID: 17555500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.